In vitro metabolism of dexamethasone (DEX) in human liver and kidney: The involvement of CYP3a4 and CYP17 (17,20 LYASE) and molecular modelling studies-Reference-Cited by-同舟云学术

In vitro metabolism of dexamethasone (DEX) in human liver and kidney: The involvement of CYP3a4 and CYP17 (17,20 LYASE) and molecular modelling studies

Published:1997-09 Issue:5 Volume:54 Page:605-611
ISSN:0006-2952
Container-title:Biochemical Pharmacology
language:en
Short-container-title:Biochemical Pharmacology

Author:

Tomlinson E.S.,Lewis D.F.V.,Maggs J.L.,Kroemer H.K.,Park B.K.,Back D.J.

Publisher

Elsevier BV

Subject

Pharmacology,Biochemistry

Reference14 articles.

1. Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation;Gentile;J Pharmacol Exp Ther,1996

2. Dexamethasone as an in vivo probe for CYP3A4;Tomlinson;Exp Toxicol Pathol,1996

3. Identification and quantification of 6β-hydroxydexamethasone as a major urinary metabolite of dexamethasone in man;Minagawa;Steroids,1986

4. Steroidogenic enzymes: Structure, function and role in regulation of steroid hormone biosynthesis;Hanukoglu;J Steroid Biochem,1995

5. Cytochrome P-450 hPCN3, a Novel Cytochrome P-450 IIIA Gene Product That Is Differentially Expressed in Adult Human Liver

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti‐inflammatory effects of dexamethasone in COVID‐19 patients: Translational population PK/PD modeling and simulation;Clinical and Translational Science;2023-07-05

2. Roles of human cytochrome P450 3A4/5 in dexamethasone 6β-hydroxylation mediated by liver microsomes and humanized liver in chimeric mice metabolically suppressed with azamulin;Drug Metabolism and Pharmacokinetics;2023-06

3. Pharmacokinetic/Pharmacodynamic Modeling of Dexamethasone Anti-Inflammatory and Immunomodulatory Effects in LPS-Challenged Rats: A Model for Cytokine Release Syndrome;Journal of Pharmacology and Experimental Therapeutics;2023-01-11

4. Deuterated Drugs and Biomarkers in the COVID-19 Pandemic;ACS Omega;2022-11-13

5. Physiologically Based Pharmacokinetic Modeling Approaches for Patients With SARS‐CoV‐2 Infection: A Case Study With Imatinib;The Journal of Clinical Pharmacology;2022-05-08